Genetic and pharmacologic disruption of interleukin-1β signaling inhibits experimental aortic aneurysm formation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 2, 2013, Pages 294-304

  Johnston, William F ^a   Salmon, Morgan ^a,b   Su, Gang ^a   Lu, Guanyi ^a   Stone, Matthew L ^a   Zhao, Yunge ^a   Owens, Gary K ^b   Upchurch, Gilbert R ^a   Ailawadi, Gorav ^a  

^a Department of Surgery ^*  (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

aneurysm; animal model surgery; aortic disease; interleukin 1 receptor antagonist; vascular inflammation

Indexed keywords

ELASTASE; ELASTIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; MESSENGER RNA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; KNOCKOUT MOUSE; MACROPHAGE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; DILATATION, PATHOLOGIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELASTIN; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHILS; PANCREATIC ELASTASE; RECEPTORS, INTERLEUKIN-1; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84872909085     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300432     Document Type: Article

References (47)

1. Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun MS, Barone GW, Bandyk D, Moneta GL, Makhoul RG. The aneurysm detection and management study screening program: validation cohort and fnal results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med. 2000;160:1425-1430.
2. Norman PE, Jamrozik K, Lawrence-Brown MM, Le MT, Spencer CA, Tuohy RJ, Parsons RW, Dickinson JA. Population based randomised controlled trial on impact of screening on mortality from abdominal aortic aneurysm. BMJ. 2004;329:1259.
3. Scott RA, Bridgewater SG, Ashton HA. Randomized clinical trial of screening for abdominal aortic aneurysm in women. Br J Surg. 2002;89:283-285.
4. Lederle FA, Larson JC, Margolis KL, Allison MA, Freiberg MS, Cochrane BB, Graettinger WF, Curb JD; Women's Health Initiative Cohort Study. Abdominal aortic aneurysm events in the women's health initiative: cohort study. BMJ. 2008;337:a1724.
5. Semmens JB, Norman PE, Lawrence-Brown MM, Holman CD. Infuence of gender on outcome from ruptured abdominal aortic aneu-rysm. Br J Surg. 2000;87:191-194.
6. Brewster DC, Cronenwett JL, Hallett JW Jr, Johnston KW, Krupski WC, Matsumura JS; Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. J Vasc Surg. 2003;37:1106-1117.
7. Prall AK, Longo GM, Mayhan WG, Waltke EA, Fleckten B, Thompson RW, Baxter BT. Doxycycline in patients with abdominal aortic aneu-rysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg. 2002;35:923-929.
8. Shimizu K, Mitchell RN, Libby P. Infammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26:987-994.
9. Brophy CM, Reilly JM, Smith GJ, Tilson MD. The role of infamma-tion in nonspecifc abdominal aortic aneurysm disease. Ann Vasc Surg. 1991;5:229-233.
10. Newman KM, Jean-Claude J, Li H, Ramey WG, Tilson MD. Cytokines that activate proteolysis are increased in abdominal aortic aneurysms. Circulation. 1994;90:II224-II227.
11. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Infammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1995;15:1145-1151.
12. Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of infammation. Eur J Immunol. 2011;41:1203-1217.
13. Pearce WH, Sweis I, Yao JS, McCarthy WJ, Koch AE. Interleukin-1 beta and tumor necrosis factor-alpha release in normal and diseased human infrarenal aortas. J Vasc Surg. 1992;16:784-789.
14. Abdul-Hussien H, Hanemaaijer R, Kleemann R, Verhaaren BF, van Bockel JH, Lindeman JH. The pathophysiology of abdominal aortic aneurysm growth: corresponding and discordant infammatory and pro-teolytic processes in abdominal aortic and popliteal artery aneurysms. J Vasc Surg. 2010;51:1479-1487.
15. Juvonen J, Surcel HM, Satta J, Teppo AM, Bloigu A, Syrjälä H, Airaksinen J, Leinonen M, Saikku P, Juvonen T. Elevated circulating levels of infammatory cytokines in patients with abdominal aortic aneu-rysm. Arterioscler Thromb Vasc Biol. 1997;17:2843-2847.
16. Carter DB, Deibel MR Jr, Dunn CJ, Tomich CS, Laborde AL, Slightom JL, Berger AE, Bienkowski MJ, Sun FF, McEwan RN. Purifcation, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature. 1990;344:633-638.
17. Usan council. List no. 366. New names. Anakinra. Clin Pharmacol Ther. 1994;56:592.
18. Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, Loeuille D, Kivitz AJ, Silver D, Appleton BE. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009;61:344-352.
19. Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos PN, Kremastinos DT. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008;117:2662-2669.
20. Abbate A, Salloum FN, Vecile E, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation. 2008;117:2670-2683.
21. Hingorani A, Ascher E, Scheinman M, Yorkovich W, DePippo P, Ladoulis CT, Salles-Cunha S. The effect of tumor necrosis factor binding protein and interleukin-1 receptor antagonist on the development of abdominal aortic aneurysms in a rat model. J Vasc Surg. 1998;28:522-526.
22. Lim WK, Fujimoto C, Ursea R, Mahesh SP, Silver P, Chan CC, Gery I, Nussenblatt RB. Suppression of immune-mediated ocular infamma-tion in mice by interleukin 1 receptor antagonist administration. Arch Ophthalmol. 2005;123:957-963.
23. Ng J, Hirota SA, Gross O, Li Y, Ulke-Lemee A, Potentier MS, Schenck LP, Vilaysane A, Seamone ME, Feng H, Armstrong GD, Tschopp J, Macdonald JA, Muruve DA, Beck PL. Clostridium diffcile toxin-induced infammation and intestinal injury are mediated by the infam-masome. Gastroenterology. 2010;139:542-552. e1.
24. López-Candales A, Holmes DR, Liao S, Scott MJ, Wickline SA, Thompson RW. Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol. 1997;150:993-1007.
25. Thompson RW, Liao S, Curci JA. Vascular smooth muscle cell apoptosis in abdominal aortic aneurysms. Coron Artery Dis. 1997;8:623-631.
26. Ailawadi G, Moehle CW, Pei H, Walton SP, Yang Z, Kron IL, Lau CL, Owens GK. Smooth muscle phenotypic modulation is an early event in aortic aneurysms. J Thorac Cardiovasc Surg. 2009;138:1392-1399.
27. Rooke TW, Hirsch AT, Misra S, et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society for Vascular Medicine; Society for Vascular Surgery. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. J Vasc Surg. 2011;54:e32-e58.
28. Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT; UK Small Aneurysm Trial Participants. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation. 2004;110:16-21.
29. McCulloch CA, Downey GP, El-Gabalawy H. Signalling platforms that modulate the infammatory response: new targets for drug development. Nat Rev Drug Discov. 2006;5:864-876.
30. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of infam-matory diseases. Blood. 2011;117:3720-3732.
31. Weber A, Wasiliew P, Kracht M. Interleukin-1beta (IL-1beta) processing pathway. Sci Signal. 2010;3:cm2.
32. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet. 1988;2:706-709.
33. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:1006-1012.
34. Lindeman JH, Rabelink TJ, van Bockel JH. Immunosuppression and the abdominal aortic aneurysm: Doctor Jekyll or Mister Hyde? Circulation. 2011;124:e463-e465.
35. Guirguis EM, Barber GG. The natural history of abdominal aortic aneu-rysms. Am J Surg. 1991;162:481-483.
36. Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E, White MR, Dinarello CA, Apte RN. IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile infammation. J Immunol. 2011;187:4835-4843.
37. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, Ennis TL, Shapiro SD, Senior RM, Thompson RW. Targeted gene disruption of matrix metal-loproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641-1649.
38. Ailawadi G, Eliason JL, Roelofs KJ, Sinha I, Hannawa KK, Kaldjian EP, Lu G, Henke PK, Stanley JC, Weiss SJ, Thompson RW, Upchurch GR Jr. Gender differences in experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2004;24:2116-2122.
39. Thompson RW, Curci JA, Ennis TL, Mao D, Pagano MB, Pham CT. Pathophysiology of abdominal aortic aneurysms: insights from the elas-tase-induced model in mice with different genetic backgrounds. Ann N Y Acad Sci. 2006;1085:59-73.
40. Eliason JL, Hannawa KK, Ailawadi G, Sinha I, Ford JW, Deogracias MP, Roelofs KJ, Woodrum DT, Ennis TL, Henke PK, Stanley JC, Thompson RW, Upchurch GR Jr. Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation. Circulation. 2005;112:232-240.
41. Anidjar S, Salzmann JL, Gentric D, Lagneau P, Camilleri JP, Michel JB. Elastase-induced experimental aneurysms in rats. Circulation. 1990;82:973-981.
42. Anidjar S, Dobrin PB, Eichorst M, Graham GP, Chejfec G. Correlation of infammatory infltrate with the enlargement of experimental aortic aneurysms. J Vasc Surg. 1992;16:139-147.
43. Herzyk DJ, Berger AE, Allen JN, Wewers MD. Sandwich ELISA formats designed to detect 17 kDa IL-1 beta signifcantly underestimate 35 kDa IL-1 beta. J Immunol Methods. 1992;148:243-254.
44. Garcia JH, Liu KF, Relton JK. Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. Am J Pathol. 1995;147:1477-1486.
45. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human inter-leukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum. 1996;39:1092-1101.
46. Braddock M, Quinn A. Targeting IL-1 in infammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. 2004;3:330-339.
47. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767-801.